151. Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study
- Author
-
Albert S. Khouri, Janet B. Serle, Jason Bacharach, Dale W. Usner, Richard A. Lewis, Puiwah Braswell, Casey C. Kopczynski, Theresa Heah, Robert Benza, John W. Boyle, Michelle Butler, Leonard Robert Cacioppo, Jose F. Cardona, Valerie A. Colborn, Douglas G. Day, David T. Douglass, Sherif M. El-Harazi, Deepta Ghate, Carl Hartman, Robert F. Haverly, Barry Katzman, Max Kim, Edward Y. Koo, Michael S. Korenfeld, Bradley Kwapiszeski, Lydia Lane, Christopher Lin, Andrew Gardner Logan, Jeffrey Raymond Lozier, Henry McQuirter, Thomas K. Mundorf, Kenneth Olander, Richard J. Ou, Gregory J. Panzo, James H. Peace, Eugene E. Protzko, Robert Ritch, Kenneth Sall, Barry A. Schechter, Samuel Eric Seltzer, Pankajkumar G. Shah, Elizabeth Sharpe, Philip Lee Shettle, David G. Shulman, Inder Paul Singh, Stacy R. Smith, Stephen E. Smith, Robert John Smyth-Medina, Robert C. Sorenson, Richard Sturm, Gregory M. Sulkowski, James D. Sutton, Michael Tepedino, Julie Tsai, Carl B. Tubbs, David B. Tukel, Thomas Richard Walters, and David L. Wirta
- Subjects
Adult ,Male ,Intraocular pressure ,genetic structures ,Ocular hypertension ,Glaucoma ,Timolol ,Benzoates ,Drug Administration Schedule ,law.invention ,Tonometry, Ocular ,03 medical and health sciences ,0302 clinical medicine ,Double-Blind Method ,Randomized controlled trial ,law ,Humans ,Medicine ,In patient ,Antihypertensive Agents ,Intraocular Pressure ,Aged ,Retrospective Studies ,030304 developmental biology ,Aged, 80 and over ,0303 health sciences ,Dose-Response Relationship, Drug ,business.industry ,Retrospective cohort study ,Middle Aged ,medicine.disease ,eye diseases ,Clinical trial ,Ophthalmology ,Treatment Outcome ,Anesthesia ,beta-Alanine ,030221 ophthalmology & optometry ,Female ,Ocular Hypertension ,sense organs ,Ophthalmic Solutions ,business ,Glaucoma, Open-Angle ,Follow-Up Studies ,medicine.drug - Abstract
To compare the intraocular pressure (IOP)-lowering efficacy and safety of netarsudil once daily (QD) and timolol twice daily (BID).Double-masked, randomized, phase 3, noninferiority study.Patients with open-angle glaucoma or ocular hypertension (unmedicated baseline IOP20 to30 mm Hg at 8:00 AM) were randomized to netarsudil ophthalmic solution 0.02% QD (PM) or timolol ophthalmic solution 0.5% BID. The primary endpoint was mean IOP at 8:00 AM, 10:00 AM, and 4:00 PM at week 2, week 6, and month 3 in patients with baseline IOP25 mm Hg (per-protocol population). Safety was recorded over the 6-month treatment period.A total of 186 patients from each treatment arm were included in the primary efficacy analysis. Netarsudil QD met the criteria for noninferiority to timolol BID. Mean treated IOP ranged from 16.3 to 17.9 mm Hg for netarsudil and 16.7 to 17.6 for timolol, with mean reductions from baseline of 3.9 to 4.7 mm Hg and 3.8 to 5.2 mm Hg, respectively. In prespecified secondary analyses, netarsudil demonstrated noninferiority to timolol in patients with baseline IOP27 mm Hg and30 mm Hg. The IOP-lowering effects of netarsudil were sustained over 6 months of treatment. No treatment-related serious adverse event (AE) was reported for either study drug. However, statistically significant reductions in mean heart rate were recorded at all study visits for the timolol group. The most frequent ocular AE among netarsudil-treated patients was conjunctival hyperemia (47.9%), which was predominately mild.Netarsudil QD (PM), a first-in-class IOP-lowering medication, was noninferior to timolol BID and was associated with tolerable ocular AEs.
- Published
- 2019
- Full Text
- View/download PDF